Literature DB >> 20975055

Clinical features of facioscapulohumeral muscular dystrophy 2.

J C de Greef1, R J L F Lemmers, P Camaño, J W Day, S Sacconi, M Dunand, B G M van Engelen, S Kiuru-Enari, G W Padberg, A L Rosa, C Desnuelle, S Spuler, M Tarnopolsky, S L Venance, R R Frants, S M van der Maarel, R Tawil.   

Abstract

OBJECTIVE: In some 5% of patients with facioscapulohumeral muscular dystrophy (FSHD), no D4Z4 repeat contraction on chromosome 4q35 is observed. Such patients, termed patients with FSHD2, show loss of DNA methylation and heterochromatin markers at the D4Z4 repeat that are similar to patients with D4Z4 contractions (FSHD1). This commonality suggests that a change in D4Z4 chromatin structure unifies FSHD1 and FSHD2. The aim of our study was to critically evaluate the clinical features in patients with FSHD2 in order to establish whether these patients are phenotypically identical to FSHD1 and to establish the effects of the (epi-) genotype on the phenotype.
METHODS: This cross-sectional study studied 33 patients with FSHD2 from 27 families, the largest cohort described to date. All patients were clinically assessed using a standardized clinical evaluation form. Genotype analysis was performed by pulsed field gel electrophoresis and PCR; D4Z4 methylation was studied by methylation-sensitive Southern blot analysis.
RESULTS: FSHD2 is identical to FSHD1 in its clinical presentation. Notable differences include a higher incidence (67%) of sporadic cases and the absence of gender differences in disease severity in FSHD2. Overall, average disease severity in FSHD2 was similar to that reported in FSHD1 and was not influenced by D4Z4 repeat size. In FSHD2, a small effect of the degree of hypomethylation on disease severity was observed.
CONCLUSIONS: Clinically, patients with FSHD2 are indistinguishable from patients with FSHD1. The present data suggest that FSHD1 and FSHD2 are the result of the same pathophysiologic process.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20975055      PMCID: PMC2974464          DOI: 10.1212/WNL.0b013e3181f96175

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  De novo facioscapulohumeral muscular dystrophy: frequent somatic mosaicism, sex-dependent phenotype, and the role of mitotic transchromosomal repeat interaction between chromosomes 4 and 10.

Authors:  S M van der Maarel; G Deidda; R J Lemmers; P G van Overveld; M van der Wielen; J E Hewitt; L Sandkuijl; B Bakker; G J van Ommen; G W Padberg; R R Frants
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

2.  Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD).

Authors:  M M O Tonini; M R Passos-Bueno; A Cerqueira; S R Matioli; R Pavanello; M Zatz
Journal:  Neuromuscul Disord       Date:  2004-01       Impact factor: 4.296

3.  Homozygosity for autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) does not result in a more severe phenotype.

Authors:  M M O Tonini; R C M Pavanello; J Gurgel-Giannetti; R J Lemmers; S M van der Maarel; R R Frants; M Zatz
Journal:  J Med Genet       Date:  2004-02       Impact factor: 6.318

4.  Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy.

Authors:  Petra G M van Overveld; Richard J F L Lemmers; Lodewijk A Sandkuijl; Leo Enthoven; Sara T Winokur; Floor Bakels; George W Padberg; Gert-Jan B van Ommen; Rune R Frants; Silvère M van der Maarel
Journal:  Nat Genet       Date:  2003-11-23       Impact factor: 38.330

5.  Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere.

Authors:  Richard J L F Lemmers; Peggy de Kievit; Lodewijk Sandkuijl; George W Padberg; Gert-Jan B van Ommen; Rune R Frants; Silvère M van der Maarel
Journal:  Nat Genet       Date:  2002-09-23       Impact factor: 38.330

6.  Diagnostic criteria for facioscapulohumeral muscular dystrophy.

Authors:  G W Padberg; P W Lunt; M Koch; M Fardeau
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

7.  Beevor's sign in facioscapulohumeral muscular dystrophy: an old sign with new implications.

Authors:  Katharina Eger; Berit Jordan; Sylvia Habermann; Stephan Zierz
Journal:  J Neurol       Date:  2009-10-17       Impact factor: 4.849

8.  Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD).

Authors:  Weihua Zeng; Jessica C de Greef; Yen-Yun Chen; Richard Chien; Xiangduo Kong; Heather C Gregson; Sara T Winokur; April Pyle; Keith D Robertson; John A Schmiesing; Virginia E Kimonis; Judit Balog; Rune R Frants; Alexander R Ball; Leslie F Lock; Peter J Donovan; Silvère M van der Maarel; Kyoko Yokomori
Journal:  PLoS Genet       Date:  2009-07-10       Impact factor: 5.917

9.  Quality of life and pain in patients with facioscapulohumeral muscular dystrophy.

Authors:  Luca Padua; Irene Aprile; Roberto Frusciante; Elisabetta Iannaccone; Monica Rossi; Rosaria Renna; Sonia Messina; Giuseppina Frasca; Enzo Ricci
Journal:  Muscle Nerve       Date:  2009-08       Impact factor: 3.217

10.  Possible phenotypic dosage effect in patients compound heterozygous for FSHD-sized 4q35 alleles.

Authors:  M Wohlgemuth; R J Lemmers; E L van der Kooi; M J van der Wielen; P G van Overveld; H Dauwerse; E Bakker; R R Frants; G W Padberg; S M van der Maarel
Journal:  Neurology       Date:  2003-10-14       Impact factor: 9.910

View more
  84 in total

1.  A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function.

Authors:  Sachiko Homma; Jennifer C J Chen; Fedik Rahimov; Mary Lou Beermann; Kendal Hanger; Genila M Bibat; Kathryn R Wagner; Louis M Kunkel; Charles P Emerson; Jeffrey Boone Miller
Journal:  Eur J Hum Genet       Date:  2011-11-23       Impact factor: 4.246

Review 2.  Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence.

Authors:  Silvère M van der Maarel; Rabi Tawil; Stephen J Tapscott
Journal:  Trends Mol Med       Date:  2011-02-01       Impact factor: 11.951

3.  Wnt/β-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells.

Authors:  Gregory J Block; Divya Narayanan; Amanda M Amell; Lisa M Petek; Kathryn C Davidson; Thomas D Bird; Rabi Tawil; Randall T Moon; Daniel G Miller
Journal:  Hum Mol Genet       Date:  2013-07-02       Impact factor: 6.150

4.  The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1.

Authors:  Sabrina Sacconi; Richard J L F Lemmers; Judit Balog; Patrick J van der Vliet; Pauline Lahaut; Merlijn P van Nieuwenhuizen; Kirsten R Straasheijm; Rashmie D Debipersad; Marianne Vos-Versteeg; Leonardo Salviati; Alberto Casarin; Elena Pegoraro; Rabi Tawil; Egbert Bakker; Stephen J Tapscott; Claude Desnuelle; Silvère M van der Maarel
Journal:  Am J Hum Genet       Date:  2013-09-26       Impact factor: 11.025

5.  Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy.

Authors:  Kenji Rowel Q Lim; Rika Maruyama; Yusuke Echigoya; Quynh Nguyen; Aiping Zhang; Hunain Khawaja; Sreetama Sen Chandra; Takako Jones; Peter Jones; Yi-Wen Chen; Toshifumi Yokota
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

6.  Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2.

Authors:  Satomi Mitsuhashi; Steven E Boyden; Elicia A Estrella; Takako I Jones; Fedik Rahimov; Timothy W Yu; Basil T Darras; Anthony A Amato; Rebecca D Folkerth; Peter L Jones; Louis M Kunkel; Peter B Kang
Journal:  Neuromuscul Disord       Date:  2013-08-31       Impact factor: 4.296

7.  Identification of two novel SMCHD1 sequence variants in families with FSHD-like muscular dystrophy.

Authors:  Jincy Winston; Laura Duerden; Matthew Mort; Ian M Frayling; Mark T Rogers; Meena Upadhyaya
Journal:  Eur J Hum Genet       Date:  2014-04-23       Impact factor: 4.246

8.  Diagnostic approach for FSHD revisited: SMCHD1 mutations cause FSHD2 and act as modifiers of disease severity in FSHD1.

Authors:  Mirjam Larsen; Simone Rost; Nady El Hajj; Andreas Ferbert; Marcus Deschauer; Maggie C Walter; Benedikt Schoser; Pawel Tacik; Wolfram Kress; Clemens R Müller
Journal:  Eur J Hum Genet       Date:  2014-11-05       Impact factor: 4.246

Review 9.  Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease.

Authors:  Charis L Himeda; Takako I Jones; Peter L Jones
Journal:  Antioxid Redox Signal       Date:  2014-12-04       Impact factor: 8.401

10.  Double SMCHD1 variants in FSHD2: the synergistic effect of two SMCHD1 variants on D4Z4 hypomethylation and disease penetrance in FSHD2.

Authors:  Marlinde L van den Boogaard; Richard J F L Lemmers; Pilar Camaño; Patrick J van der Vliet; Nicol Voermans; Baziel G M van Engelen; Adolfo Lopez de Munain; Stephen J Tapscott; Nienke van der Stoep; Rabi Tawil; Silvère M van der Maarel
Journal:  Eur J Hum Genet       Date:  2015-03-18       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.